CYPS317 / FibroBiologics - LARVOL DELTA

FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) - "Upcoming Milestones:...(i) Complete pre-clinical IND-enabling studies for the treatment of psoriasis with CYPS317, FibroBiologics’ fibroblast spheroid product candidate, and submit IND; (ii) Complete pre-clinical IND-enabling studies for the treatment of multiple sclerosis with CYMS101, FibroBiologics’ fibroblast spheroid product candidate, and submit IND."

IND • Preclinical • Multiple Sclerosis • Psoriasis